Based on the significant unmet need in Alzheimers disease as well as a number of indicative data points, we felt we had a responsibility to explore semaglutides potential, despite a low likelihood of success, Martin Holst Lange, chief scientific officer at Novo Nordisk said in a press release
If you know upfront that indefinite treatment is not financially or personally viable, that knowledge should shape your initial goals and your investment in building lifestyle habits during the treatment window
Primarily prescribed for the management of T2D, these medications have also shown increased public interest in chronic weight management
While the GLP-1RA drugs have traditionally been used in type 2 diabetics, their ability to cause weight loss has captured the minds and imaginations of patients, providers, and drug manufacturers alike
Share this article
Wegovy: $1,300 $1,350 per month without insurance